242.05 0.00 (0.00%)
After hours: 4:18PM EST
|Bid||241.00 x 5000|
|Ask||246.03 x 100|
|Day's Range||240.87 - 244.48|
|52 Week Range||156.50 - 248.97|
|PE Ratio (TTM)||46.11|
|Earnings Date||Jan 30, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||236.00|
Illumina, Inc. today announced that it will issue results for fourth quarter and fiscal year 2017 following the close of market on Tuesday, January 30, 2018.
SAN DIEGO, Jan. 15, 2018 /PRNewswire/ -- Luna DNA, the first and only genomic and medical research knowledge base powered by the blockchain and owned by its community, announced today Dawn Barry as president. In this role, Barry will be responsible for leading operations, communicating and implementing company mission, and guiding overall strategy, direction, and growth. Barry will present at the 13th Precision Medicine World Conference (PMWC) on January 24, 2018, in Silicon Valley.
On a record day for the indexes, Illumina stock rose on a product announcement and positive outlook, and e.l.f. Beauty fell following a lowered growth forecast.
Thermo Fisher Scientific and Illumina, Inc. today announced they have signed a commercial agreement that enables Illumina to sell Ion AmpliSeq technology to researchers who conduct scientific studies on Illumina’s next-generation sequencing platforms.
Illumina, Inc. announced today the launch of the iSeq™ 100 Sequencing System. The new, next-generation sequencing system delivers exceptional data accuracy, at a low capital cost, making Illumina technology available to virtually any lab.
Illumina, the dominant maker of DNA sequencers that are used in drug discovery, medicine, and biological research, is unveiling a new toy: A $19,900, one-cubic-foot box that puts DNA sequencing in the reach of many more scientists.
Jan 8 (Reuters) - Guangzhou Kingmed Diagnostics Group Co Ltd : * SAYS UNIT SIGNS AGREEMENT WITH ILLUMINA TO BUY GENES-RELATED TESTING EQUIPMENT SUCH AS MINISEQ Source text in Chinese: http://bit.ly/2m8GPFr ...
Illumina, Inc. and KingMed Diagnostics today announced an agreement to jointly develop novel oncology and hereditary disease testing applications utilizing Illumina’s next-generation sequencing technology.
A surge in China's markets and several key analyst upgrades helped send U.S. stocks to a positive start to the year.
Swing trades have less leeway to ride out market storms. The answer: quick action on defense and a solid offense by taking profits on the way up.
On December 7, 2017, Thermo Fisher Scientific announced the launch of a new targeted NGS (next-generation sequencing) research panel.
Illumina (ILMN) harbors hopes about recent launches like NovaSeq S4 flow cell and reagent kit for its NovaSeq 6000 System. A low margin scenario due to the NovaSeq launch is a concern.
Illumina, Inc. today announced that its executives will be presenting at the following investor conference and invited investors to participate via webcast.
Categories: Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives Illumina, Inc. a score of 88. Our analysis is based on comparing Illumina, Inc. with the following peers – PerkinElmer, Inc., Pacific Biosciences of California, Inc., Agilent Technologies, Inc., Thermo Fisher Scientific Inc., Danaher Corporation, Precipio, Inc., Quest Diagnostics Incorporated, Luminex Corp and Fluidigm Corporation (PKI-US, PACB-US, ... Read more (Read more...)
Community-owned database empowers individuals with cryptocurrency for contributing genomic data SAN DIEGO , Dec. 18, 2017 /PRNewswire/ -- Luna DNA , the first and only genomic and medical research knowledge ...
The market leaders have shifted since the first half of year. One way or another healthcare is going to see some big changes, so it’s a good time to position yourself in solid healthcare firms that will win, regardless of Washington. The following are my top seven A-rated healthcare stocks to buy now.
Jim Cramer listed the J.P. Morgan's Healthcare Conference's best and worst performers judging by the stock market's reaction.
Francis deSouza, Illumina president and CEO, talks about what's driving the company's growth, the unveiling of its $20,000 desktop sequencer and the future of genome sequencing.